What is the share price of Aragen Life Sciences Ltd?

Company share prices are keep on changing according to the market conditions. The current trading price of Aragen Life Sciences Ltd on 01-Jan-1970 05:30:00 at 05:30 is .

What is the P/E ratio of Aragen Life Sciences?

The latest standalone P/E ratio of Aragen Life Sciences as of 01-Jan-1970 is 0.00.

What is the P/B ratio of Aragen Life Sciences Ltd?

The latest standalone P/B ratio of Aragen Life Sciences Ltd as of 01-Jan-1970 is 0.00.

What is the 52-week high and low of Aragen Life Sciences Ltd?

The 52-week high of Aragen Life Sciences Ltd is Rs. and the 52-week low is Rs. .

Aragen Life Sciences Ltd

Name: Aragen Life Sciences Ltd
Brand: Aragen Life Sciences

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 0 NSE: Pharmaceuticals & Drugs | Small Cap | Aragen Life Sciences Share Price

BSE Share Price
Not Listed

Aragen Life Sciences Ltd

Share Analysis – Quality, Valuation Zone, Price Trend & DeciZen Rating BSE: 0 NSE: Pharmaceuticals & Drugs | Small Cap | Aragen Life Sciences Share Price

BSE Share Price
Not Listed

Key Metrics

Valuation Multiples

Market Cap

₹0 Cr.

Current Price

₹0

52-Week Low / High

₹0 / 0

TTM EPS

TTM Sales

Book Value per Share

P/E Ratio

Industry PE

54.5

Price to Book (P/B)

Price to Sales (P/S)

EV/EBITDA

Dividend Yield

INF%

Profitability Efficiency

Return on Equity (ROE)

12.27%

Return on Capital Employed (ROCE)

15.21%

Return on Assets (ROA)

6.83%

Operating Profit Margin

25.7%

Net Profit Margin

11.83%

Gross Profit Margin

25.8%

Growth Momentum
1-yr vs 3-yr growth

Sales Growth (1 Year)

Improving versus 3-year growth rate

13.15%

Operating Profit Growth (1 Year)

Improving versus 3-year growth rate

23%

Net Profit Growth (1 Year)

Improving versus 3-year growth rate

42.83%

Asset Quality

Promoter Holding

Pledged shares (%) of Promoter's holding (%)

Reserves

Equity

₹0 Cr.

Face Value

All Time Low / High

- / -

10 Year X-Ray :

Analysis of Financial Track Record (Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end)

Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end

Value Creation ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
ROCE % ⓘ	10.6%	21.4%	14.5%	12.7%	15.7%	21%	22.5%	22.6%	15.3%	16.1%	-
Growth Parameters ⓘ
Sales ⓘ	327	551	577	683	812	950	1,236	1,560	1,460	1,652	683
Sales YoY Gr.	-	68.5%	4.8%	18.4%	18.9%	17.1%	30.1%	26.2%	-6.4%	13.2%	-
Adj EPS ⓘ	2.1	3.3	3.3	3.6	4.2	7.4	10.2	12.3	9.3	11	0
YoY Gr.	-	58.9%	-1.2%	10.2%	17%	76.9%	37.8%	20.2%	-24%	17.5%	-
BVPS (₹) ⓘ	26.6	27.9	30.5	32.9	33.4	41.3	51	58.7	66	99.9	0
Adj Net Profit ⓘ	41.3	66.1	65.4	72	84.2	149	209	251	191	238	NAN
Cash Flow from Ops. ⓘ	-42.1	111	97.5	87.5	233	209	358	276	344	335	-
Debt/CF from Ops. ⓘ	-2.2	1.1	2.3	1.9	1.3	1.3	1.5	1.8	1.7	1	-

CAGR ⓘ

	9 Years	5 Years	3 Years	1 Years
Sales ⓘ	19.7%	15.3%	10.2%	13.2%
Adj EPS ⓘ	20.3%	21.2%	2.4%	17.5%
BVPSⓘ	15.8%	24.5%	25.1%	51.5%
Share Price	-	-	-	-

Key Financial Parameters ⓘ

	Mar'16	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	TTM
Return on Equity % ⓘ	7.7	12.1	11.1	11.2	12.5	19.7	22.3	22.2	14.7	13.3	0
Op. Profit Mgn % ⓘ	19.8	24.8	22.6	24.5	25.5	28.3	31.6	31.6	28.6	27.8	NAN
Net Profit Mgn % ⓘ	12.6	12	11.3	10.6	10.4	15.7	16.9	16.1	13.1	14.4	NAN
Debt to Equity ⓘ	0.2	0.2	0.4	0.3	0.4	0.3	0.5	0.4	0.5	0.2	-
Working Cap Days ⓘ	275	160	171	185	179	156	135	121	194	265	0
Cash Conv. Cycle ⓘ	27	19	35	39	40	37	34	38	56	59	0

Valuation of Aragen Life Sciences - Consolidated

YTD 1Y 3Y 5Y 10Y Max

Analyst's Notes

No data found!

Management X-Ray

Shareholding Pattern

No Data To Display

Promoter's Holding & Share Pledging

Financials

PARTICULARS	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	Mar'26
Sales	620.72	659.29	792.94	950.52	1,133.28	1,387.36	1,736.60	1,657.58	1,845.11	2,178.39
Operating Expenses ⓘ +	488.28	522.40	633.09	712.14	814.92	981.29	1,237.64	1,232.31	1,389.99	1,618.59
Manufacturing Costs	150.24	156.20	191.53	213.02	246	295.55	397.35	133.05	149.86	167.19
Material Costs	81.33	100.04	116.84	129.73	139.89	173.63	210.83	392.07	469.58	590.21
Employee Cost	190.53	199.04	219.65	271.25	329.47	411.17	511.94	572.17	617.35	680.78
Other Costs ⓘ	66.18	67.12	105.07	98.14	99.56	100.95	117.52	135.01	153.20	180.41
Operating Profit ⓘ	132.43	136.89	159.85	238.38	318.36	406.07	498.96	425.27	455.12	559.81
Operating Profit Margin (%)	21.3%	20.8%	20.2%	25.1%	28.1%	29.3%	28.7%	25.7%	24.7%	25.7%
Other Income ⓘ +	44.24	29.09	19.49	6.80	18.37	15.84	15.43	26.39	25.19	47.20
Exceptional Items ⓘ	0	-11.19	0	0	0	0	0	0	0	-11.44
Interest ⓘ	7.99	11.31	20.71	18.50	19.33	25.65	40.55	35.03	38.07	40.51
Depreciation ⓘ	48.74	56.89	65.84	87.23	100.49	128.90	167.29	191.79	185.87	199
Profit Before Tax ⓘ	119.93	86.59	92.78	139.46	216.90	267.37	306.55	224.83	256.37	356.05
Tax ⓘ	47.88	29.47	31.64	39.98	52.63	69.90	86.68	64.73	75.99	98.40
Profit After Tax	72.06	57.12	61.14	99.48	164.28	197.46	219.87	160.10	180.38	257.64
PAT Margin (%)	11.6%	8.7%	7.7%	10.5%	14.5%	14.2%	12.7%	9.7%	9.8%	11.8%
Adjusted EPS (₹)	3.6	2.8	3.0	5.0	10.8	9.7	10.6	7.7	8.3	11.8
Dividend Payout Ratio (%)	16.70%	19.40%	22%	23.30%	22%	29.80%	25%	25.90%	25.30%	25.40%

PARTICULARS	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	Mar'26
Equity and Liabilities
Shareholders Fund +	531.24	568.27	621.44	647.22	908.41	1,032.19	1,157.85	1,276.01	2,025.73	2,173.38
Share Capital ⓘ	66.98	66.98	66.98	66.98	66.98	68.14	204.41	204.41	216.99	216.99
Reserves ⓘ	464.26	501.29	554.46	580.24	841.43	964.05	953.43	1,071.60	1,808.74	1,956.39
Debt +	120.73	227.62	168.34	316.68	316.46	567.44	442.86	369.84	320.54	344.74
Long Term Debt	25.13	105.87	111.81	206.64	173.80	474.47	355.89	180.94	141	142.37
Short Term Debt	95.60	121.75	56.52	110.04	142.66	92.97	86.97	188.91	179.54	202.37
Minority Interest	0	0	0	0	79.17	51.31	54.77	56.76	57.27	0
Trade Payables	73.35	77.43	112.46	110.29	114.09	126.32	114.79	119.13	156.65	198.55
Others Liabilities ⓘ	59.27	79.11	112.09	163.90	176.25	284.14	362.65	1,030.14	1,072.16	1,197.17
Total Liabilities ⓘ	784.58	952.43	1,014.32	1,238.09	1,594.39	2,061.40	2,132.91	2,851.88	3,632.35	3,913.84
Fixed Assets
Net Fixed Assets ⓘ +	406.88	517.92	535.68	585.20	686.73	1,080.92	1,185.97	1,301.83	1,488.59	1,674.91
Gross Block	498.21	666.47	750.89	879.21	1,066.98	1,575.25	1,838.63	2,183.23	2,535.66	2,883.55
Accumulated Depreciation	91.34	148.55	215.21	294.01	380.26	494.33	652.66	881.40	1,047.07	1,208.64
CWIP ⓘ	59.74	15.18	41.73	100.90	80.89	32.17	169.58	311.75	433.78	300.02
Investments ⓘ	1.07	5.26	0.18	1.19	0.18	0.19	0.21	0.21	0.21	3.41
Inventories	29.06	41.73	77.39	73.07	67.09	98.75	65.92	72.15	82.31	86.57
Trade Receivables	120.40	123.71	177.48	186.29	254.79	243.15	329.01	350.36	436.30	598.75
Cash Equivalents	71.74	126.97	45.43	143.76	308.06	368.98	156.57	185.80	290.24	258
Others Assets ⓘ	95.68	121.66	136.43	147.67	196.64	237.24	225.66	629.79	900.93	992.19
Total Assets ⓘ	784.58	952.43	1,014.32	1,238.09	1,594.39	2,061.40	2,132.91	2,851.88	3,632.35	3,913.84

PARTICULARS	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	Mar'26
Cash Flow From Operating Activity ⓘ +	110.69	97.82	102.76	256.14	338.30	357.46	275.64	388.57	335.71	375.86
PBT ⓘ	119.93	86.59	92.78	139.46	216.90	267.37	306.55	224.83	256.37	356.05
Adjustment ⓘ	46.25	54.51	86.34	117.76	170.12	148.01	212.55	226.13	205.84	224.55
Changes in Working Capital ⓘ	-24.93	-18.33	-78.3	32.57	9.91	21.19	-158.45	14.79	-58.56	-105.46
Tax Paid ⓘ	-30.57	-24.94	1.94	-33.66	-58.63	-79.11	-85.01	-77.18	-67.94	-99.28
Cash Flow From Investing Activity ⓘ +	-88.02	-180.39	0.08	-187.95	-220.15	-494.25	-352.64	-338.87	-698.99	-186.76
Capex	-156	-121.85	-99.54	-158.72	-154.76	-351.85	-376.25	-385.29	-369.43	-287.82
Net Investments	50.63	-66.61	94.25	-32.85	0	0	62.46	39.22	-342.93	72.71
Others ⓘ	17.35	8.08	5.37	3.62	-65.39	-142.40	-38.85	7.20	13.37	28.35
Cash Flow From Financing Activity ⓘ +	-21.17	81.33	-100.81	50.87	-122.58	234.93	-101.42	5.88	330.34	-193.45
Net Proceeds from Shares ⓘ	0.88	0	0	0	0	16.28	0	0	620.10	0
Net Proceeds from Borrowing ⓘ	11.95	80.17	-3.85	68.13	-23.84	274.91	0	17.84	-158.63	-53.01
Interest Paid ⓘ	-10.11	-9.53	-18.80	-13.04	-16.72	-17.90	-37.75	-41.79	-52.77	-43.16
Dividend Paid ⓘ	-0.98	-14.44	-13.19	-43.71	-66.22	0	-59.73	-53.53	-40.40	-45.11
Others ⓘ	-22.91	25.14	-64.97	39.50	-15.80	-38.35	-3.94	83.37	-37.96	-52.17
Net Cash Flow ⓘ	1.50	-1.23	2.04	119.06	-4.44	98.15	-178.41	55.58	-32.94	-4.35

PARTICULARS	Mar'17	Mar'18	Mar'19	Mar'20	Mar'21	Mar'22	Mar'23	Mar'24	Mar'25	Mar'26
Ratios
ROE (%)	13.48	10.39	10.28	15.68	21.12	20.35	20.08	13.16	10.93	12.27
ROCE (%)	19.18	13.19	13.98	17.49	21.24	20.75	21.02	14.22	13.13	15.21
Asset Turnover Ratio	0.79	0.76	0.81	0.84	0.8	0.76	0.83	0.67	0.57	0.58
PAT to CFO Conversion(x)	1.54	1.71	1.68	2.57	2.06	1.81	1.25	2.43	1.86	1.46
Working Capital Days
Receivable Days	73	67.60	69.30	69.80	71	65.50	60.10	74.60	77.60	86
Inventory Days	14.10	19.60	27.40	28.90	22.60	21.80	17.30	15.20	15.20	14
Payable Days	312.20	275.10	296.60	313.40	292.70	252.70	208.70	108.90	107.20	109.80

Top 5 Mutual Funds Holding

Last Visited Stocks

Announcements

Aragen Life Sciences Ltd FAQs

The current trading price of Aragen Life Sciences on 01-Jan-1970 05:30 is ₹0.00.

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of 31-Dec-1969 the market cap of Aragen Life Sciences stood at ₹0.00 Cr

The latest P/E ratio of Aragen Life Sciences as of 31-Dec-1969 is 0.00.

The latest P/B ratio of Aragen Life Sciences as of 31-Dec-1969 is 0.00.

The 52-week high of Aragen Life Sciences is ₹0.00 and the 52-week low is ₹0.00.

The TTM revenue is Trailing Twelve Months sales. The TTM revenue/sales of Aragen Life Sciences is ₹683 ( Cr.) .

Data is not available for this company.

No data found

About Aragen Life Sciences Ltd

No data to display

You have 49 views remaining as a Guest User. To get DeciZen Rating of 3,500+ Stocks based on their Quality, Valuation and Price Trend Login Now

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045

Compliance Officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com	Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com	Telephone: +919860919463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com	Telephone: +919175899463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Aragen Life Sciences Ltd

Aragen Life Sciences Ltd

10 Year X-Ray :